Once weekly recombinant human erythropoietin treatment for cancer-induced anemia in children with acute lymphoblastic leukemia receiving maintenance chemotherapy: a randomized case-controlled study. (avab uue akna)

Abdelrazik N, Fouda M

Allikas‎: Hematology 2007;12(6):533-41.

Indekseeritud‎: PubMed 17852440

DOI‎: 10.1080/10245330701521572

https://www.ncbi.nlm.nih.gov/pubmed/17852440 (avab uue akna)

Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: results of a randomized clinical trial. (avab uue akna)

Cabanillas ME, Kantarjian H, Thomas DA, Mattiuzzi GN, Rytting ME, Bruera E, Xiao L, Bekele BN, Foudray MC, Cortes JE.

Allikas‎: Cancer 2012;118(3):848-55.

Indekseeritud‎: PubMed 21751205

DOI‎: 10.1002/cncr.26341

https://www.ncbi.nlm.nih.gov/pubmed/21751205 (avab uue akna)

Recombinant human erythropoietin beta therapy: an effective strategy to reduce transfusion requirement in children receiving anticancer treatment. (avab uue akna)

Corapcioglu F, Aksu G, Basar EZ, Demirel A, Oncel S, Mutlu A

Allikas‎: Pediatr Hematol Oncol 2008;25(6):509-21.

Indekseeritud‎: PubMed 18728970

DOI‎: 10.1080/08880010802235132

https://www.ncbi.nlm.nih.gov/pubmed/18728970 (avab uue akna)

Recombinant human erythropoietin beta: the effect of weekly dosing on anemia, quality of life, and long-term outcomes in pediatric cancer patients. (avab uue akna)

Durmaz O, Demirkaya M, Sevinir B

Allikas‎: Pediatr Hematol Oncol 2011;28(6):461-8.

Indekseeritud‎: PubMed 21707225

DOI‎: 10.3109/08880018.2011.570857

https://www.ncbi.nlm.nih.gov/pubmed/21707225 (avab uue akna)

Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial. (avab uue akna)

Engert A, Josting A, Haverkamp H, Villalobos M, Lohri A, Sökler M, Zijlstra J, Sturm I, Topp MS, Rank A, Zenz T, Vogelhuber M, Nogova L, Borchmann P, Fuchs M, Flechtner HH, Diehl V.

Allikas‎: J Clin Oncol 2010;28(13):2239-45.

Indekseeritud‎: PubMed 20368566

DOI‎: 10.1200/JCO.2009.25.1835

https://www.ncbi.nlm.nih.gov/pubmed/20368566 (avab uue akna)

Treatment patterns and outcomes in management of solid cancer patients suffering from anemia in Penang hospital. (avab uue akna)

Hassan BA, Yusoff ZB

Allikas‎: Asian Pac J Cancer Prev 2011;12(6):1573-6.

Indekseeritud‎: PubMed 22126501

https://www.ncbi.nlm.nih.gov/pubmed/22126501 (avab uue akna)

Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia. (avab uue akna)

Hernandez E, Ganly P, Charu V, Dibenedetto J, Tomita D, Lillie T, Taylor K; ARANESP 20030232 Study Group

Allikas‎: Curr Med Res Opin 2009;25(9):2109-20.

Indekseeritud‎: PubMed 19601709

DOI‎: 10.1185/03007990903084164

https://www.ncbi.nlm.nih.gov/pubmed/19601709 (avab uue akna)

Hemoglobin response and improvements in quality of life in anemic children with cancer receiving myelosuppressive chemotherapy. (avab uue akna)

Hinds PS, Hockenberry M, Feusner J, Hord JD, Rackoff W, Rozzouk BI

Allikas‎: J Support Oncol 2005;3(6 Suppl 4):10-1.

Indekseeritud‎: PubMed 16355549

https://www.ncbi.nlm.nih.gov/pubmed/16355549 (avab uue akna)

The efficacy of recombinant human erythropoietin in treatment chemotherapy induced anemia in children diagnosed with a solid cancer. (avab uue akna)

Hiradfar A, Banihosseinian M

Allikas‎: Iran J Ped Hematol Oncol 2014;4(4):151-9.

Indekseeritud‎: PubMed 25598955

https://www.ncbi.nlm.nih.gov/pubmed/25598955 (avab uue akna)

2007 Standards, Options, and Recommendations: use of erythropoiesis-stimulating agents (ESA: epoetin alfa, epoetin beta, and darbepoetin) for the management of anemia in children with cancer. (avab uue akna)

Marec-Berard P, Chastagner P, Kassab-Chahmi D, Casadevall N, Marchal C, Misset JL, Ray-Coquard I.

Allikas‎: Pediatr Blood Cancer 2009;53(1):7-12.

Indekseeritud‎: PubMed 19229970

DOI‎: 10.1002/pbc.21953

https://www.ncbi.nlm.nih.gov/pubmed/19229970 (avab uue akna)

Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients. (avab uue akna)

Michallet M, Goldet K, Sobh M, Morisset S, Chelghoum Y, Thomas X, Barraco F, Ducastelle S, Labussière H, Renzullo C, Paillet C, Pivot C, Straaten PB, Denis A, Termoz A, Detrait M, Nicolini FE, Jaisson-Hot I.

Allikas‎: Cancer 2013;119(1):107-14.

Indekseeritud‎: PubMed 22744794

DOI‎: 10.1002/cncr.27686

https://www.ncbi.nlm.nih.gov/pubmed/22744794 (avab uue akna)

Erythropoietic growth factors for children with cancer: a systematic review of the literature. (avab uue akna)

Mystakidou K, Potamianou A, Tsilika E

Allikas‎: Curr Med Res Opin 2007;23(11):2841-7.

Indekseeritud‎: PubMed 17910805

DOI‎: 10.1185/030079907x242601

https://www.ncbi.nlm.nih.gov/pubmed/17910805 (avab uue akna)

Double-blind, placebo-controlled study of quality of life, hematologic end points, and safety of weekly epoetin alfa in children with cancer receiving myelosuppressive chemotherapy. (avab uue akna)

Razzouk BI, Hord JD, Hockenberry M, Hinds PS, Feusner J, Williams D, Rackoff WR

Allikas‎: J Clin Oncol 2006;24(22):3583-9.

Indekseeritud‎: PubMed 16877725

DOI‎: 10.1200/JCO.2005.03.4371

https://www.ncbi.nlm.nih.gov/pubmed/16877725 (avab uue akna)

The role of recombinant erythropoietin in childhood cancer. (avab uue akna)

Shankar AG

Allikas‎: Oncologist 2008;13(2):157-66.

Indekseeritud‎: PubMed 18305061

DOI‎: 10.1634/theoncologist.2007-0126

https://www.ncbi.nlm.nih.gov/pubmed/18305061 (avab uue akna)

Efficacy and safety of iorEPOCIM for chemotherapy- or radiotherapy-induced anemia in pediatric cancer patients. (avab uue akna)

Vargas A, Mendoza I, Uranga R, González A, Martínez L, Caballero I, Piedra P, Saurez G, Verdecia M, Cabanas R

Allikas‎: MEDICC Rev 2010;12(3):27-31.

Indekseeritud‎: PubMed 20697335

DOI‎: 10.37757/MR2010.V12.N3.7

https://www.ncbi.nlm.nih.gov/pubmed/20697335 (avab uue akna)

A single institutional experience: is epoetin alpha effective in anemic children with cancer? (avab uue akna)

Yilmaz D, Cetingül N, Kantar M, Oniz H, Kansoy S, Kavakli K

Allikas‎: Pediatr Hematol Oncol 2004;21(1):1-8.

Indekseeritud‎: PubMed 14660300

https://www.ncbi.nlm.nih.gov/pubmed/14660300 (avab uue akna)

Single dose darbepoetin alfa is useful in reducing red cell transfusions in leukemic children receiving chemotherapy. (avab uue akna)

Zachariah M, Elshinawy M, Alrawas A, Bashir W, Elbeshlawi I, Tony S, Wali Y

Allikas‎: Pediatr Hematol Oncol 2014;31(5):442-7.

Indekseeritud‎: PubMed 24088186

DOI‎: 10.3109/08880018.2013.824527

https://www.ncbi.nlm.nih.gov/pubmed/24088186 (avab uue akna)

Early epoetin alfa treatment in children with solid tumors. (avab uue akna)

Zoubek A, Kronberger M

Allikas‎: Med Pediatr Oncol 2002;39(4):459-62.

Indekseeritud‎: PubMed 12203664

DOI‎: 10.1002/mpo.10186

https://www.ncbi.nlm.nih.gov/pubmed/12203664 (avab uue akna)

Intravenous iron for critically ill children. Comparison of three dose regimens. (avab uue akna)

Butragueño-Laiseca L, de la Mata Navazo S, Sánchez Galindo AC, Santiago Lozano MJ

Allikas‎: Pediatr Blood Cancer 2024;71(1):e30734.

Indekseeritud‎: PubMed 37880937

DOI‎: 10.1002/pbc.30734

https://pubmed.ncbi.nlm.nih.gov/37880937/ (avab uue akna)

Intravenous iron sucrose for children with iron deficiency failing to respond to oral iron therapy. (avab uue akna)

Crary SE, Hall K, Buchanan GR.

Allikas‎: Pediatr Blood Cancer 2011;56(4):615-9.

Indekseeritud‎: PubMed 21298748

DOI‎: 10.1002/pbc.22930

https://www.ncbi.nlm.nih.gov/pubmed/21298748 (avab uue akna)

Intravenous iron sucrose for children with iron deficiency anemia. (avab uue akna)

Kaneva K, Chow E, Rosenfield CG, Kelly MJ

Allikas‎: J Pediatr Hematol Oncol 2017;39(5):e259-62.

Indekseeritud‎: PubMed 28562517

DOI‎: 10.1097/MPH.0000000000000879

https://www.ncbi.nlm.nih.gov/pubmed/28562517 (avab uue akna)

Advances in Pediatric Intravenous Iron Therapy. (avab uue akna)

Mantadakis E.

Allikas‎: Pediatr Blood Cancer 2016;63(1):11-6.

Indekseeritud‎: PubMed 26376214

DOI‎: 10.1002/pbc.25752

https://www.ncbi.nlm.nih.gov/pubmed/26376214 (avab uue akna)

The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents. (avab uue akna)

Mhaskar R, Wao H, Miladinovic B, Kumar A, Djulbegovic B.

Allikas‎: Cochrane Database Syst Rev 2016;(2):CD009624.

Indekseeritud‎: PubMed 26845108

DOI‎: 10.1002/14651858.CD009624.pub2

https://www.ncbi.nlm.nih.gov/pubmed/26845108 (avab uue akna)

Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. (avab uue akna)

Pedrazzoli P, Farris A, Del Prete S, Del Gaizo F, Ferrari D, Bianchessi C, Colucci G, Desogus A, Gamucci T, Pappalardo A, Fornarini G, Pozzi P, Fabi A, Labianca R, Di Costanzo F, Secondino S, Crucitta E, Apolloni F, Del Santo A, Siena S.

Allikas‎: J Clin Oncol 2008;26(10):1619-25.

Indekseeritud‎: PubMed 18375891

DOI‎: 10.1200/JCO.2007.12.2051

https://www.ncbi.nlm.nih.gov/pubmed/18375891 (avab uue akna)

Intravenous low molecular weight iron dextran in children with iron deficiency anemia unresponsive to oral iron. (avab uue akna)

Plummer ES, Crary SE, McCavit TL, Buchanan GR

Allikas‎: Pediatr Blood Cancer 2013;60(11):1747-52.

Indekseeritud‎: PubMed 23832487

DOI‎: 10.1002/pbc.24676

https://www.ncbi.nlm.nih.gov/pubmed/23832487 (avab uue akna)